Skip to content
  • Home
  • About Us
        • About APLAR
          • APLAR Milestones
          • President Message
        • Committees
          • APLAR Directors
          • Executive Committee
          • Other Committees
        • Membership
          • Member National Organizations
          • Constitution & Terms of Reference
          • Membership Application
          • Membership Update
  • Academy
        • APLAR Academy
          • Governance
          • Membership
        • Short Course
          • Upcoming Course
          • Past Course
        • Academy Webinar
          • Upcoming Webinar
          • Past Webinar
        • Grand Round
          • Upcoming Grand Round
          • Past Grand Round
          • Discussion Forum
          • Grand Round Blackboard
        • ASPIRE Grant
          • About APLAR ASPIRE
          • ASPIRE Core Training Modules
          • ASPIRE Implementation Toolkit
  • About SIG
  • AYR
        • ABOUT AYR
          • AYR Board
          • Committee
          • AYR Membership
        • AYR Webinar
          • Upcoming Webinar
          • Past Webinar
          • AYR Blackboard
          • Discussion Forum
  • Collaboration
        • APLAR ESOR
          • ESOR Application
          • Post Event Submission
          • Online Submission
          • EULAR School of Rheumatology
        • Exchange Programme
          • Exchange Programe Application
          • Online Submission
          • EULAR Exchange Program
        • APLAR MNO Patronage
          • Patronage Application
          • Online Submission
          • EULAR Collaborations
        • Center Of Excellence
          • APLAR CoEs
          • New Application
          • Renew CoE Application
          • Online Submission
  • Grants and Awards
        • Grant
          • COPCORD Grant
          • Congress Travel Grant
          • Research Grant
          • Fellowship Grant
        • Award
          • Master Award
  • Events
        • Congress
          • Upcoming Congress
          • Past Congress
        • Events
          • Upcoming Events
          • Past Events
        • Gallery
  • Publications
        • Published Journal
          • SIG Publication
          • COVID – 19 Publication
        • IJRD
        • Voice Of APLAR
  • Patient Education

AYR 2nd Webinar Blackboard

CT Thorax Reading in CTD-ILD

A 42-year-old female patient is recently diagnosed with diffuse cutaneous systemic sclerosis (anti-Scl-70 positive). She does not have any respiratory symptoms. The lung function test shows no sign of restriction (FVC 91%; FEV1 83%; FEV1%/FVC 91%; TLC 99%).

Which further investigation would you perform?

Your Answer is Incorrect

Answer with Detailed explanation

The correct answer is Chest CT

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is diagnosed in about 50% of patients diagnosed with SSc and is associated with a high mortality rate. As a substantial number of patients with SSc-ILD are asymptomatic, screening for SSc-ILD is of paramount importance. As the sensitivity and diagnostic accuracy of chest radiographs in SSc-ILD are very low, they are not indicated for ILD screening.

Lung function test is an important tool in the initial assessment and follow-up of patients with SSc-ILD. However, as the lung function test's false-negative rate is substantial, it cannot rule out SSc-ILD. Consequently, a current evidence-based European consensus statement suggests performing a screening HRCT in all patients with SSc-ILD at baseline.

Reference:

  • Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.
  • Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.
  • Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.

By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria


Your Answer is Correct

Answer with Detailed explanation

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is diagnosed in about 50% of patients diagnosed with SSc and is associated with a high mortality rate. As a substantial number of patients with SSc-ILD are asymptomatic, screening for SSc-ILD is of paramount importance. As the sensitivity and diagnostic accuracy of chest radiographs in SSc-ILD are very low, they are not indicated for ILD screening.

Lung function test is an important tool in the initial assessment and follow-up of patients with SSc-ILD. However, as the lung function test's false-negative rate is substantial, it cannot rule out SSc-ILD. Consequently, a current evidence-based European consensus statement suggests performing a screening HRCT in all patients with SSc-ILD at baseline.

Reference:

  • Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.
  • Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.
  • Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.

By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria

  • Address: 1 Scotts Road #24-10 Shaw Center Singapore 228208
  • Email: secretariat@aplar.org

Social Media

Subscribe

By providing email, I agree to receive all corespondances from APLAR

ALL RIGHTS RESERVED © 2023 | APLAR.ORG